OTO. O. Tkachuk-Hryhorchuk

O. O. Tkachuk-Hryhorchuk

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


O. O. Tkachuk-Hryhorchuk has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Adjunctive empagliflozin therapy in endocrine-driven heart failure with preserved ejection fraction after thyroid cancer surgery

    by O. M. Didushko, M. V. Bielinskyi, A. S. Herashchenko, N. B. Nyshchuk-Oliinyk, O. O. Tkachuk-Hryhorchuk, A. Y. Pavliskyi

    Survivors of differentiated thyroid cancer after total thyroidectomy form a growing population with increased long-term cardiovascular risk related to chronic thyroid hormone imbalance and lifelong L-thyroxine replacement. In this setting, hypothyroid cardiomyopathy with preserved left ventricular ejection fraction is associated with elevated N-terminal fragment of pro-B-type natriuretic pept ide (NT-proBNP), diastolic dysfunction, atrial remodeling and endothelial impairment. Data on disease-modifying treatment for this endocrine-driven heart failure with preserved ejection fraction (HFpEF)-like phenotype remain limited. Objective — to assess the effect of adding empagliflozin to standard beta-blocker and angiotensin-converting enzyme inhibitor therapy on left ventricular diastolic function, endothelial function and galectin-3 levels in post-thyroidectomy thyroid cancer patients with hypothyroid cardiomyopathy and preserved ejection fraction. Materials and methods. This prospective controlled study included 61 adults (57,2±7,3 years, 48 female, 23 male) after total thyroidectomy for thyroid cancer with heart failure symptoms, elevated NT-proBNP and left ventricular ejection fraction ≥50%. Patients received either standard therapy or standard therapy plus empagliflozin 10 mg/day for 6 months. Results. Baseline clinical characteristics, thyroid status, L-thyroxine dose and NT-proBNP levels were comparable between groups. Standard therapy alone produced only modest improvement in diastolic indices, flow-mediated dilation (FMD), galectin-3 and NT-proBNP. In contrast, empagliflozin was associated with greater reductions in E/e′, larger increases in e′ velocities, a more pronounced decrease in left atrial volume index, stronger improvement in FMD, and greater declines in galectin-3 and NT-proBNP. In multivariable linear mixed-effects models, time × treatment interactions for E/e′ FMD, galectin-3 and NT-proBNP remained significant. Empagliflozin was well tolerated, with no serious drug-related adverse events. Conclusions. In post-thyroidectomy thyroid cancer patients with hypothyroid cardiomyopathy and preserved ejection fraction, empagliflozin added to standard therapy was associated with greater improvement in diastolic and endothelial function and with larger reductions in galectin-3 and NT-proBNP than standard treatment alone. These findings support its potential cardio- and vasculoprotective role in endocrine-driven HFpEF phenotypes and justify larger randomized trials.

  • Open Access

    The effect of empagliflozin on fractalkine levels in patients with type 2 diabetes mellitus

    by O. M. Didushko, M. V. Bielinskyi, A. S. Herashchenko, O. Y. Kobrynska, O. O. Tkachuk-Hryhorchuk

    Type 2 diabetes mellitus (T2DM) is characterized by chronic hyperglycemia and low grade systemic inflammation. Among chemokines involved in diabetic inflammation, CX3CL1 (fractalkine) plays a prominent role: elevated levels are linked to insulin resistance and vascular complications. Sodium–glucose co transporter 2 (SGLT2) inhibitors, particularly empagliflozin, not only lower glucose but also exert anti inflammatory effects that may modulate CX3CL1. Objective — to evaluate the effect of empagliflozin compared with standard therapy on fractalkine (CX3CL1) and glycated hemoglobin levels in T2DM patients with varying body mass index and to determine whether the effect on CX3CL1 is mediated by changes in HbA1c. Materials and methods. A prospective study enrolled 110 adults with T2DM divided by body mass index (BMI): group I (normal weight, n=30), group II (overweight, n=40) and group III (obesity, n=40). Each group was randomised into subgroups A (standard therapy: lifestyle modification, diet, 200 min/week moderate intensity walking, metformin 850—2000 mg/day and statins) or B (standard therapy plus empagliflozin 10 mg/day for six months). HbA1c was measured by high performance liquid chromatography; CX3CL1 was quantified using a solid phase sandwich ELISA. Changes in biomarkers were analysed, percentage reductions were calculated and a linear regression (mediation analysis) evaluated whether HbA1c change mediated the effect on CX3CL1. Results. Baseline characteristics (mean age ~43 years, disease duration ~4 years) did not differ among groups. After six months, empagliflozin recipients had greater HbA1c reductions: −18.9% vs −9.2% in normal weight patients, −12.3% vs −1.6% in overweight and −7.2% vs −0.2% in obese patients (p < 0.05). Fractalkine levels declined significantly only with empagliflozin: reductions of 32.6% (group I), 23.9% (group II) and 15.3% (group III), whereas no changes were observed under standard therapy (p > 0.05). Mediation analysis demonstrated that empagliflozin therapy was associated with an additional ∼98 pg/ml reduction in CX3CL1 irrespective of HbA1c change (β=98.14; 95% CI 57.1—139.2; p=0.005), while the coefficient for ΔHbA1c was not significant (p=0.855), indicating a direct effect. Conclusions. Addition of empagliflozin to standard care yields substantial improvement in glycemic control and significant lowering of CX3CL1 across BMI categories. The identified direct effect on fractalkine suggests that the anti-inflammatory benefits of SGLT2 inhibitors extend beyond glucose lowering. These findings support the use of empagliflozin in T2DM patients, particularly those with overweight or obesity, to mitigate inflammatory and cardiorenal complications.

  • Open Access

    Impact of type 2 diabetes mellitus on heart failure with preserved ejection fraction depending on the presence of atrial fibrillation

    by N.M. Kulaiets, V.M. Kulaiets, O.O. Tkachuk-Hryhorchuk, N.B. Nyshchuk-Oliinyk

    Background. Cardiovascular diseases, including heart failure (HF) and heart failure with preserved ejection fraction (HFpEF), pose a global health challenge. HFpEF is on the rise, especially among the elderly and those with conditions like diabetes, obesity, and hypertension. Type 2 diabetes mellitus (T2DM) often coexists with HFpEF, and atrial fibrillation (AF) further complicates matters due to shared risk factors. The purpose of this study is to comprehensively investigate the influence of type 2 diabetes mellitus on cardiac function and biomarker profiles in patients with heart failure with preserved ejection fraction in the presence or absence of atrial fibrillation. Mate­rials and methods. This was a cohort, single-center study. Four hundred and forty-eight patients with HFpEF were examined. They were divided into 4 groups: group 1 — 189 patients with HFpEF alone; group 2 — 39 patients with HFpEF and T2DM; group 3 — 176 patients with HFpEF and atrial fibrillation; group 4 — 44 patients with HFpEF, AF, T2DM. Results. T2DM may contribute to a slightly older patient population in HFpEF, but age alone is not a primary discriminator. T2DM alone does not substantially impact left ventricular mass index but, when combined with AF, it does. T2DM is associated with an increased left atrial volume index, and AF intensifies this effect. T2DM influences diastolic function, with AF exacerbating it. T2DM affects left ventricular filling pressure, and AF worsens this in HFpEF. T2DM also influences left ventricular systolic function, further compromised when combined with AF in HFpEF patients. Galectin-3 levels are elevated in HFpEF patients with T2DM, further exacerba­ted with AF. NT-proBNP levels are influenced by T2DM and worsened with the combination of AF in HFpEF. SST2 levels are elevated in HFpEF patients with T2DM, further increased with AF, indicating myocardial fibrosis and adverse remodeling. Conclusions. The interaction between T2DM and AF in HFpEF patients creates a synergistic effect, resulting in significant cardiac structural and functional alterations. Novel biomarkers such as galectin-3, NT-proBNP, and sST2 emerge as valuable diagnostic tools, reflecting the complex pathophysiological processes in HFpEF.

  • Open Access

    КАФЕДРА ЗАГАЛЬНОЇ ТА СУДИННОЇ ХІРУРГІЇ - 40 РОКІВ ДОСВІДУ.

    by Іван Гудз, Степан Геник, Антон Симчич, Олег Попадюк, Дмитро Михальчук, Ірина Дмитрів, Юрій Диб'яК, Віктор Оринчак, Мар'яНа Федорків, Ірина Нестеренко, et al.

    У статті підведено підсумки діяльності однієї із провідних кафедр Івано-Франківського національного медичного університету – загальної та судинної хірургії впродовж 40 років. Це етап за яким тривала і клопітка навчально-методична та цілеспрямована клінічна і науково-дослідницька робота цілих поколінь. За роки існування кафедри вже сформувалися наукові школи, які гідно представляють нашу Альма-Матер не тільки в Україні, але і далеко за її межами. Власне, знання, практичні навички, перший досвід діяльності в сфері медицини – все це отримують майбутні лікарі, засвоюючи навчальні програми кожної з дисциплін. А вони, лаконічно, з року в рік переходять від фундаментальних дисциплін, які становлять основу розуміння і аналізу майбутнім лікарем всіх невидимих неозброєним оком змін всередині організму хворого, до клінічних, які нерозривно зв’язують в єдине ціле патологічні процеси в середині організму із зовнішніми їхніми проявами. Тільки таке поєднання в аналітичній роботі лікаря є гарантом правильності вибору ним діагностичних підходів, лікувальних методик, реабілітаційних механізмів, тобто всього, що потрібно зробити, щоб максимально повноцінно відновити якість життя пацієнта.